Back to all studies
🫁
Phase 4
Respiratory
in-person
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison t…
Sponsored by Regeneron Pharmaceuticals
Compensation
$500–$2,500
Duration
3 months
Location
Nationwide
About this study
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication. The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medica…
Who can participate
- • Adults aged 12–80
- • All genders welcome
- • Diagnosed with or experiencing asthma
- • Able to attend in-person clinic visits
What's included
- • Compensation up to $2,500
- • All study-related medical care at no cost
- • Lab work, screenings, and physician consultations
- • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.
Ready to Find a Paid Study?
Join over 100,000 people who have been matched with clinical studies. It's free, fast, and could change your life.